{"title":"Association of Leukotriene A4 Hydrolase polymorphisms and risk of extrapulmonary tuberculosis","authors":"Pooja Singh Gaur, Surya Kant, Rachna Chaturvedi","doi":"10.25303/1809rjbt1910197","DOIUrl":null,"url":null,"abstract":"Genetic risk assessment of tuberculosis development and genotypic variation influence the gene and protein expression of leukotriene A4 hydrolase (LTA4H) at various sites of tuberculosis. The relationship between the genotype and phenotype of LATH4A was investigated in relation to the genetic risk assessment of extrapulmonary tuberculosis (EPTB). This study included 137 patients with EPTB and age-sex-matched 137 normal controls of the same ethnicity. LTA4H genotyping was performed using restriction fragment polymorphisms (RFLP) and protein level was analyzed using enzyme-linked immunosorbent assay (ELISA). The LTAH4 (rs.197833A/G) AG (codominant) and GG (recessive) genotypes showed 1.86 and 1.88-fold higher risks (p=0.0004 and p<0.0001 respectively) of developing EPTB. LTA4H (rs.2660898 T/G) TG (codominant) and GG (recessive) genotypes significantly increased the risk (OR:1.69, p=0.0001 and OR;1.77 p=0.008 respectively) of EPTB. Similarly, LTA4H (rs. 2540474) AG (codominant) and GG (recessive) genotypes (OR; 1.58 95% CI:1.22- 2.04, p<0.0001; OR, 1.86; 95%CI 1.37-2.52, p<0.0001) increased the risk of developing ETTB. The LTB4 protein levels were significantly higher in EPTB cases (mean ± SD; 3096.10±1287.6 pg/mL) than in controls (2304.50±644.15 pg/mL) (p<0.0001). LTA4H recessive variants influence protein levels (functional genetics), resulting in risk of EPTB.","PeriodicalId":21091,"journal":{"name":"Research Journal of Biotechnology","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research Journal of Biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25303/1809rjbt1910197","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0
Abstract
Genetic risk assessment of tuberculosis development and genotypic variation influence the gene and protein expression of leukotriene A4 hydrolase (LTA4H) at various sites of tuberculosis. The relationship between the genotype and phenotype of LATH4A was investigated in relation to the genetic risk assessment of extrapulmonary tuberculosis (EPTB). This study included 137 patients with EPTB and age-sex-matched 137 normal controls of the same ethnicity. LTA4H genotyping was performed using restriction fragment polymorphisms (RFLP) and protein level was analyzed using enzyme-linked immunosorbent assay (ELISA). The LTAH4 (rs.197833A/G) AG (codominant) and GG (recessive) genotypes showed 1.86 and 1.88-fold higher risks (p=0.0004 and p<0.0001 respectively) of developing EPTB. LTA4H (rs.2660898 T/G) TG (codominant) and GG (recessive) genotypes significantly increased the risk (OR:1.69, p=0.0001 and OR;1.77 p=0.008 respectively) of EPTB. Similarly, LTA4H (rs. 2540474) AG (codominant) and GG (recessive) genotypes (OR; 1.58 95% CI:1.22- 2.04, p<0.0001; OR, 1.86; 95%CI 1.37-2.52, p<0.0001) increased the risk of developing ETTB. The LTB4 protein levels were significantly higher in EPTB cases (mean ± SD; 3096.10±1287.6 pg/mL) than in controls (2304.50±644.15 pg/mL) (p<0.0001). LTA4H recessive variants influence protein levels (functional genetics), resulting in risk of EPTB.
期刊介绍:
We invite you to contribute Research Papers / Short Communications / Review Papers:
-In any field of Biotechnology, Biochemistry, Microbiology and Industrial Microbiology, Soil Technology, Agriculture Biotechnology.
-in any field related to Food Biotechnology, Nutrition Biotechnology, Genetic Engineering and Commercial Biotechnology.
-in any field of Biotechnology related to Drugs and Pharmaceutical products for human beings, animals and plants.
-in any field related to Environmental Biotechnolgy, Waste Treatment of Liquids, Soilds and Gases; Sustainability.
-in inter-realted field of Chemical Sciences, Biological Sciences, Environmental Sciences and Life Sciences.
-in any field related to Biotechnological Engineering, Industrial Biotechnology and Instrumentation.
-in any field related to Nano-technology.
-in any field related to Plant Biotechnology.